Poseida Therapeutics Past Earnings Performance
Past criteria checks 0/6
Poseida Therapeutics has been growing earnings at an average annual rate of 4.3%, while the Biotechs industry saw earnings growing at 15% annually. Revenues have been growing at an average rate of 55.6% per year.
Key information
4.3%
Earnings growth rate
50.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 55.6% |
| Return on equity | -128.7% |
| Net Margin | -131.9% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?
May 21
Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 27%
Apr 09Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T Advancement
Mar 17Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?
Jan 24Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Price Boosted 43% But Its Business Prospects Need A Lift Too
Dec 18New Forecasts: Here's What Analysts Think The Future Holds For Poseida Therapeutics, Inc. (NASDAQ:PSTX)
Aug 13Little Excitement Around Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Revenues As Shares Take 44% Pounding
Apr 17Poseida Therapeutics: Collaboration Agreement With Roche Helps Validate Genetic Engineering Tech
Sep 04Poseida Therapeutics GAAP EPS of -$0.69 beats by $0.08, revenue of $2.7M beats by $1.77M
Aug 11Poseida jumps 56% as Roche eyes CAR-T drugs in deal worth up to $6B
Aug 03Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25
May 15Poseida Therapeutics: Genome Engineering For Safer Cell Therapies
Oct 30What Type Of Shareholders Make Up Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Registry?
Mar 19Did Poseida Therapeutics, Inc. (NASDAQ:PSTX) Insiders Buy Up More Shares?
Jan 25Poseida Therapeutics (PSTX) Presents At 62nd Virtual Annual Meeting of ASH - Slideshow
Dec 09FDA lifts clinical hold on Poseida's prostate cancer cell therapy study
Nov 02Revenue & Expenses Breakdown
How Poseida Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 83 | -109 | 35 | 0 |
| 31 Dec 23 | 65 | -123 | 37 | 0 |
| 30 Sep 23 | 50 | -131 | 38 | 0 |
| 30 Jun 23 | 157 | -29 | 39 | -8 |
| 31 Mar 23 | 139 | -45 | 40 | 0 |
| 31 Dec 22 | 130 | -64 | 38 | 0 |
| 30 Sep 22 | 152 | -29 | 38 | 0 |
| 30 Jun 22 | 35 | -142 | 37 | 79 |
| 31 Mar 22 | 33 | -145 | 37 | 0 |
| 31 Dec 21 | 31 | -125 | 36 | 0 |
| 30 Sep 21 | 0 | -163 | 34 | -76 |
| 30 Jun 21 | 0 | -155 | 31 | -49 |
| 31 Mar 21 | 0 | -139 | 27 | -23 |
| 31 Dec 20 | 0 | -130 | 23 | 0 |
| 30 Sep 20 | 0 | -117 | 20 | 95 |
| 30 Jun 20 | 0 | -104 | 17 | 84 |
| 31 Mar 20 | 0 | -102 | 17 | 75 |
| 31 Dec 19 | 0 | -87 | 18 | 60 |
| 30 Sep 19 | 0 | -76 | 17 | 51 |
| 31 Dec 18 | 0 | -44 | 10 | 31 |
| 30 Sep 18 | 0 | -36 | 9 | 25 |
| 31 Dec 17 | 3 | -20 | 5 | 19 |
| 31 Dec 16 | 10 | -5 | 5 | 9 |
Quality Earnings: PSTX is currently unprofitable.
Growing Profit Margin: PSTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PSTX is unprofitable, but has reduced losses over the past 5 years at a rate of 4.3% per year.
Accelerating Growth: Unable to compare PSTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PSTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: PSTX has a negative Return on Equity (-128.68%), as it is currently unprofitable.